Market Intelligence, Clinical Progress, and High-Purity Reagents for Autoimmune & B-Cell Malignancy Development.
B Lymphoid Kinase (BLK), a Src-family non-receptor tyrosine kinase, is a critical node in B-cell receptor (BCR) signaling with emerging therapeutic relevance in lymphoid malignancies and autoimmune disorders. As the field pivots from pan-Src inhibition to BLK-selective targeting, rigorous biochemical and cellular assays are required to navigate the high homology within the Src kinase family.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for BLK drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Active Kinase | BLK Wild-Type Recombinant Kinase Domain. High purity (>95%), Endotoxin <1EU/µg. Sequence Verified. Active conformation (Tyr-phosphorylated). | View BLK Products |
| Resistance Panel | BLK Gatekeeper Mutant (T338I). ATP-binding site mutant for resistance profiling. Theoretical MW verified. | View BLK Products |
| Negative Control | BLK Kinase-Dead Mutant (K262R). Catalytically inactive for specificity controls in cellular assays. | View BLK Products |
| Gene Delivery | BLK Promise-ORF / Lentivirus. Full-length ORF for stable cell line construction (BaF3, HEK293T, or B-cell lines). | View BLK Products |
| Benchmark Antibody | Anti-BLK Recombinant Antibody. Research-grade positive control for Western blot, Flow cytometry, and IP. | View BLK Products |
| Validator | BLK siRNA Set. For knockdown verification and assay specificity checks. | View BLK Products |
| Selectivity Counter-Screen | SRC (Src Proto-Oncogene). Closest paralog; essential for selectivity profiling. | View SRC Products |
| Related Target - LYN | LYN (Src-Family Kinase). Essential for BCR co-signaling and selectivity counter-screening. | View LYN Products |
| Parallel Target | BTK (Bruton's Tyrosine Kinase). Parallel BCR pathway; combination therapy rationale. | View BTK Products |
| Pathway Partner | SYK (Spleen Tyrosine Kinase). Upstream BCR signaling node; synergistic inhibition studies. | View SYK Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Src Family Selectivity (High homology with SRC/LYN/FYN) | High purity BLK (>95%) with strictly matched SFK ortholog panel (SRC, LYN, FYN, HCK, YES) for parallel enzymatic screening. |
| Active vs. Inactive Conformation Stability | HEK293/Baculovirus expressed BLK with native activating phosphorylation (Tyr389) preserved; DFG-in conformation stabilized. |
| Gatekeeper Resistance Prediction | Pre-made T338I gatekeeper mutant plus additional activation loop mutants for ATP-competitive inhibitor resistance profiling. |
| Cellular Target Engagement & BCR Signaling | Lentivirus particles (titer >1E8 TU/ml) for stable BLK-overexpressing Ramos or BaF3 cell lines; suitable for BCR signaling assays. |
| False Positive Elimination | Validated siRNA set plus kinase-dead mutant (K262R) included for off-target effect control. |
| Drug Resistance Mutation Profiling | BLK mutant kinase domain proteins (gatekeeper/activation loop variants). Custom mutation service available. |
Live BLK R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of BLK is transitioning from historical pan-Src inhibition (e.g., dasatinib, bosutinib) toward selective BLK modulation for B-cell driven autoimmune diseases and specific lymphoma subsets. As first-generation multi-kinase inhibitors face selectivity limitations, the next wave of R&D focuses on allosteric inhibitors and proteolysis-targeting chimeras (PROTACs) capable of distinguishing BLK from closely related Src family members. The emerging emphasis on autoimmune indications (systemic lupus erythematosus, rheumatoid arthritis) requires assay systems capable of detecting subtle shifts in BCR signaling thresholds. The next wave of R&D is targeting highly selective allosteric inhibitors to avoid off-target toxicity associated with pan-Src inhibition.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Takeda, Bristol Myers Squibb, Nimbus, Early-stage Biotechs | SLE, RA, B-Cell Lymphoma, Leukemia | Selectivity Panel (Need BLK vs. SRC/LYN purified proteins) |
| PROTAC Degraders | Arvinas, C4 Therapeutics (Pipeline), Academic/Biotech | Refractory DLBCL, B-Cell Lymphoma | Cellular Degradation Assay (Need lentivirus for stable BLK-expressing lines) |
| Allosteric Inhibitors | Academic Consortia, Emerging Biotech | Autoimmune Diseases | Conformational State Assay (Need active vs. inactive BLK proteins) |
| Combination Therapy (with BTKi) | Various Clinical Trials, Early Discovery | SLE, RA, CLL, DLBCL | Synergy Quantification (Need SYK + BLK + BTK triple panel) |
Molecular Differentiation & Assay Strategy
To develop best-in-class BLK-targeted drugs, the following differentiation criteria and corresponding assay strategies must be met:
-
Selectivity & Affinity: BLK's ATP-binding pocket is highly homologous with other Src family members (especially LYN, FYN, SRC, LCK). Best-in-class drugs require at least 100-fold selectivity to avoid T-cell toxicity from Lck inhibition and broad tissue toxicity from Src inhibition. Assay: Kinase activity inhibition profiling using a recombinant protein panel covering the entire Src family for IC50 determination.
-
Mechanism of Action (PROTACs): Efficient ternary complex formation and ubiquitin-mediated degradation. Assay: Cellular degradation experiments (Western Blot / HiBiT knock-in system), relying on high-quality stable cell lines and high-specificity antibodies.
-
Safety & Resistance: Overcoming potential ATP-binding pocket mutations. Assay: Mutant kinase activity testing and binding kinetics (SPR/BLI) analysis.
-
Conformational State: Type II (DFG-out) inhibitors may offer slower dissociation rates and longer target residence. Assay: Differential scanning fluorimetry (DSF) or SPR with different conformation proteins.
TarMart Solution
TarMart provides a comprehensive BLK R&D toolkit through "rational design":
- High-purity recombinant kinase: BLK kinase domain expressed using baculovirus/insect cell system, ensuring natural folding and high specific activity for high-throughput drug screening and crystallography (Sequence Verified, High Purity >95%).
- Src family counter-screening panel: Provides homologous proteins such as LYN, FYN, LCK, SRC, HCK, YES to facilitate rapid validation of highly selective molecules.
- Target validation tools: Provides validated siRNA and lentiviral ORF vectors to support mechanistic studies of intracellular pathways.
- Resistance profiling: Pre-made T338I gatekeeper mutant and additional activation loop mutants for early compound screening.
Related Target Recommendations
For cross-selling, the following synergistic pathway or homologous targets are recommended:
- LYN / FYN / SRC: As Src family homologous proteins, they are essential counter-screening targets for evaluating off-target effects.
- BTK (Bruton's tyrosine kinase): A key downstream node of the B-cell receptor (BCR) signaling pathway, with highly synergistic biological mechanisms with BLK, suitable for developing combination therapy regimens.
- SYK (Spleen Tyrosine Kinase): Upstream of BLK, directly regulating BLK activation. Dual SYK/BLK inhibition shows synergistic effects in B-cell malignancies.